Previous studies have shown that ENO1 silencing induces Bax, diminishes Bcl-2, and decreases phosphorylation levels of PI3K and AKT in breast cancer; ENO1 silencing results in cell cycle arrest in gastric cancer cells; ENO1 silencing attenuates MAPK activity of p38-MAPK in lung cancer cells; and ENO1 upregulation induces apoptosis in neuroblastoma27–30. Here, BCL2 is linked to breast carcinoma.